Addex Therapeutics Ltd American Depositary Shares

Addex Therapeutics invested CHF 2 million in Stalicla, a clinical-stage company focusing on precision medicine for neurodevelopmental disorders. The investment supports Stalicla's autism drug candidates and clinical trials, with Addex CEO Tim Dyer joining Stalicla's Board of Directors.

Stalicla, a Swiss clinical-stage biotech company, secured CHF 2 million in financing from Addex Therapeutics to advance its precision medicine neurodevelopmental disorder programs, including preparing for Series C financing and progressing clinical trials for autism and substance use disorder treatments.

Addex Therapeutics reported a strong cash position of CHF2.8 million at the end of Q1 2025. The company's GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models, and it regained rights to its phase 2 mGlu2 PAM asset.

Addex Therapeutics, a clinical-stage biopharmaceutical company, announced that it will issue its Q1 2025 financial results and provide a business update on June 19, 2025. The company's GABAB PAM candidate has demonstrated robust anti-tussive activity in multiple chronic cough preclinical models.

Addex Therapeutics announced that it will present preclinical data on its GABAB positive allosteric modulator cough program at the American Cough Conference. The company's lead drug candidate is ready to start IND enabling studies.